G. Ricciuti

Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease.

R. Cianci, M. Von Heland, S. Lai, 2019, European review for medical and pharmacological sciences.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

P. Zinzani, L. Baldini, R. Marasca, 2015, The oncologist.

Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study

E. Iannitto, A. Guarini, C. Minoia, 2020, European journal of haematology.

Autologous stem cell transplantation in multiple myeloma.

G. Martinelli, A. Falcone, C. Cerchione, 2020, Panminerva medica.

Combination of rituximab and nonpegylated liposomal doxorubicin (R‐NPLD) as front‐line therapy for aggressive non‐Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single‐center retrospective study

F. Angrilli, M. Federico, S. Luciani, 2018, Hematological oncology.

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study

E. Iannitto, M. Federico, F. Merli, 2015, Leukemia & lymphoma.

Lymphoma R-COMP as a first-line treatment for Splenic Marginal Zone Lymphoma . A Fondazione Italiana Linfomi phase II study

E. Iannitto, M. Federico, F. Merli, 2015 .